nortriptyline has been researched along with Polyneuropathies in 2 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Polyneuropathies: Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Barohn, RJ | 1 |
Gajewski, B | 1 |
Pasnoor, M | 1 |
Brown, A | 1 |
Herbelin, LL | 1 |
Kimminau, KS | 1 |
Mudaranthakam, DP | 1 |
Jawdat, O | 1 |
Dimachkie, MM | 1 |
Iyadurai, S | 1 |
Stino, A | 1 |
Kissel, J | 1 |
Pascuzzi, R | 1 |
Brannagan, T | 1 |
Wicklund, M | 1 |
Ahmed, A | 1 |
Walk, D | 1 |
Smith, G | 1 |
Quan, D | 1 |
Heitzman, D | 1 |
Tobon, A | 1 |
Ladha, S | 1 |
Wolfe, G | 1 |
Pulley, M | 1 |
Hayat, G | 1 |
Li, Y | 1 |
Thaisetthawatkul, P | 1 |
Lewis, R | 1 |
Biliciler, S | 1 |
Sharma, K | 1 |
Salajegheh, K | 1 |
Trivedi, J | 1 |
Mallonee, W | 1 |
Burns, T | 1 |
Jacoby, M | 1 |
Bril, V | 1 |
Vu, T | 1 |
Ramchandren, S | 1 |
Bazant, M | 1 |
Austin, S | 1 |
Karam, C | 1 |
Hussain, Y | 1 |
Kutz, C | 1 |
Twydell, P | 1 |
Scelsa, S | 1 |
Kushlaf, H | 1 |
Wymer, J | 1 |
Hehir, M | 1 |
Kolb, N | 1 |
Ralph, J | 1 |
Barboi, A | 1 |
Verma, N | 1 |
Ahmed, M | 1 |
Memon, A | 1 |
Saperstein, D | 1 |
Lou, JS | 1 |
Swenson, A | 1 |
Cash, T | 1 |
Kaeser, HE | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)[NCT02260388] | Phase 4 | 402 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Higher scores for fatigue represents worse outcome (more fatigue). T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 Weeks
Intervention | T-Score (Mean) |
---|---|
Nortriptyline | 53.6 |
Duloxetine | 55.4 |
Pregabalin | 56.7 |
Mexiletine | 51.6 |
"Higher scores for pain interference represents worse outcome (more pain interference) T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 weeks
Intervention | T-Score (Mean) |
---|---|
Nortriptyline | 56.4 |
Duloxetine | 56.5 |
Pregabalin | 60.0 |
Mexiletine | 54.5 |
"Higher scores for sleep disturbance represents worse outcome (more sleep disturbance).~T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population.~Higher scores equals more of the concept being measured" (NCT02260388)
Timeframe: 12 weeks
Intervention | T-Score (Mean) |
---|---|
Nortriptyline | 58.9 |
Duloxetine | 58.9 |
Pregabalin | 58.3 |
Mexiletine | 59.1 |
"SF-12v2® Health Survey Standard The Optum™ SF-12v2® Health Survey is a shorter version of the SF-36v2® Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view.~Survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores.~Scores are calibrated so that 50 is the average score or norm, standard deviation = 10.~Higher scores indicate better health for both mental and physical component summary scores." (NCT02260388)
Timeframe: 12 weeks
Intervention | Norm-Based Standardization Score (Mean) | |
---|---|---|
Mental Component Score | Physical Component Score | |
Duloxetine | 50.9 | 42.1 |
Mexiletine | 51.3 | 43.7 |
Nortriptyline | 51.0 | 42.8 |
Pregabalin | 47.2 | 40.0 |
1 trial available for nortriptyline and Polyneuropathies
Article | Year |
---|---|
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
Topics: Adult; Aged; Analgesics; Bayes Theorem; Comparative Effectiveness Research; Duloxetine Hydrochloride | 2021 |
1 other study available for nortriptyline and Polyneuropathies
Article | Year |
---|---|
[Therapy of polyneuritides].
Topics: Butyrophenones; Chlorpromazine; Glucocorticoids; Humans; Hypoxia; Imipramine; Methotrimeprazine; Nor | 1971 |